Andre Goy, M.D., M.S.

Chair, Department of Oncology

Andre Goy, M.D., M.S., is Chairperson and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at the John Theurer Cancer Center at HackensackUMC, a member of Hackensack Meridian Health. He also serves as the Lydia Pfund chair for Lymphoma at the Seton Hall-Hackensack Meridian School of Medicine, chief science officer of Regional Cancer Care Associates, and professor of medicine at Georgetown University.

Dr. Goy is widely-known for his work in mantle cell lymphoma where he was the lead investigator for the development of the three FDA approved drugs in the U.S. for mantle cell lymphoma: from the first proteasome inhibitor bortezomib (Velcade) in 2006, to the first immunomodulator lenalidomide (Revlimid) in 2013 and the first BTK inhibitor ibrutinib (Imbruvica) in 2013 as well. He also participated in the pilot study for the first anti-CD20 monoclonal antibody approved in blood cancers: rituximab (Rituxan), which has had a profound impact in the management of B-cell lymphoma and leukemia as well as autoimmune disorders.

Dr. Goy’s interest as a lymphoma researcher focuses on novel therapies and new strategies to improve the outcome of lymphoma patients. He is currently leading numerous trials using novel agents or combinations in lymphomas including new monoclonal antibodies, Bcl-2 inhibitors and second generation kinase inhibitors among others. He is also working with his team exploring new non–chemotherapy options in certain subtypes of lymphoma.

Dr. Goy has published extensively and serves as reviewer for many journals in the field of hematology and oncology research.

Dr. Goy received his medical degree from University Joseph Fourier in Grenoble, France. He completed his training in hematology oncology at the Faculte of Medicine Cochin Port Royal in Paris and received a Masters in Tumor Immunology from University Pierre and Marie Curie and Pasteur Institute in Paris as well as a Master’s degree in Experimental Oncology from Kremlin Bicetre and Gustave Roussy Institute in Paris as well. He continued his training and care at Memorial Sloan-Kettering and M.D. Anderson Cancer Center and joined the John Theurer Cancer Center in 2005.